ARTICLE | Clinical News

Oral ANAVEX 2-73: Additional Phase IIa data

August 1, 2016 7:00 AM UTC

Anavex reported additional data from 32 patients with mild to moderate AD in an open-label, crossover, Australian Phase IIa trial of ANAVEX 2-73 showing that mean MMSE scores and ADCS-ADL scores were “maintained” through 31 weeks of treatment. The company said that a stable MMSE and ADCS-ADL score is considered a positive outcome due to a “disease state where progression is invariable over time.” ANAVEX 2-73 was also associated with a “sustained benefit” in psychomotor function, attention and working memory components of Cogstate Tasks over 31 weeks. Furthermore, ANAVEX 2-73 significantly reduced mean HAM-D score at week 31 compared to baseline (p<0.05). ...